The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia

Leukemia & Lymphoma
Meletios A DimopoulosGerasimos Pangalis

Abstract

Several studies have indicated that age, hemoglobin and serum albumin are among the most important prognostic factors for survival of patients with Waldenstrom's macroglobulinemia (WM). Furthermore, recent data indicate that serum b2-microglobulin may be also significant. The recently proposed International Staging System (ISS) for multiple myeloma is based on serum albumin and b2-microglobulin. We designed a study to assess this model in patients with WM. Our analysis included 83 previously untreated patients with WM who required systemic treatment and in whom pretreatment values for both serum albumin and b2-microglobulin were available. Based on these variables the patients were stratified into three ISS stages. Stage I: albumin > or = 3.5 g/dl and b2-microglobulin < 3.5 mg/dl, stage II: albumin < 3.5 g/dl and b2-microglobulin < 3.5 mg/gl or b2-microglobulin 3.5-5.5 mg/dl and stage III: b2-microglobulin > 5.5 mg/dl. Low albumin (< 3.5 g/dl) and high b2-microglobulin (> or = 3.5 mg/dl) were recorded in 45% and 52% of patients respectively. The distribution of patients in the three ISS stages was: stage I: 30%, stage II: 43% and stage III: 27%. The median overall survival from the date of treatment initiation was 115 months. T...Continue Reading

References

Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T FaconP Fenaux
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A DimopoulosM Dalakas
Feb 13, 2001·European Journal of Haematology·E C HatzimichaelK L Bourantas
Dec 12, 2001·British Journal of Haematology·R García-SanzUNKNOWN Spanish Group for the Study of Waldenström Macroglobulinaemia and PETHEMA (Programme for the Study and Treatment of Haematol
Apr 30, 2003·Seminars in Oncology·Giampaolo MerliniPaolo G Gobbi
Jul 26, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosUNKNOWN Greek Myeloma Study Group

❮ Previous
Next ❯

Citations

Jul 10, 2012·Haematologica·Esteban BraggioRafael Fonseca
Oct 16, 2012·Haematologica·Florence Nguyen-KhacUNKNOWN Groupe d’Etude des Lymphomes de l’Adulte (GELA)
Sep 13, 2014·Hematology/oncology Clinics of North America·Steven P TreonGiampaolo Merlini
Jan 11, 2014·Expert Review of Hematology·Ilyas SahinIrene M Ghobrial
Jan 16, 2007·British Journal of Haematology·E M OcioR Fonseca
May 24, 2015·Blood·Steven P Treon
Mar 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosSteven P Treon
Apr 12, 2017·Hematological Oncology·Evan RosenbaumShahzad Raza
Feb 17, 2007·Blood·Arun Vijay, Morie A Gertz
Nov 19, 2010·Expert Review of Hematology·Jennifer StedmanIrene M Ghobrial
Jan 18, 2019·Experimental and Therapeutic Medicine·Tian-Ze MaYong-Geun Kwak
Feb 6, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·S Peter WuOla Landgren

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.